NASDAQ · Biotechnology

Innoviva, Inc. (INVA) Stock

$21.21 +1.63% NASDAQ: INVA Healthcare

Valuation

MetricValue
Price$21.21
Market Cap$1.57B
P/E Ratio4.21
P/B Ratio1.22
P/S Ratio3.41
EPS (TTM)$3.30
52-Week High$25.15
52-Week Low$16.52
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE30.03%
ROA20.98%
ROCE9.82%
Gross Margin76.20%
Operating Margin14.85%
Net Margin80.56%
Debt/Equity0.22
Current Ratio14.56

Annual Financials (USD)

Metric20212022202320242025
Revenue$392.0M$331.0M$310.0M$359.0M$425.0M
Operating Profit$375.0M$207.0M$114.0M$167.0M$164.0M
Net Profit$266.0M$214.0M$180.0M$23.0M$271.0M
EPS$2.87$2.37$2.20$0.36$3.30
Op Margin95.7%62.5%36.7%46.5%38.5%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$926.0M$1.2B$1.2B$1.3B$1.6B
Total Liabilities$400.0M$666.0M$569.0M$610.0M$462.0M
Cash$202.0M$291.0M$194.0M$305.0M$551.0M
Borrowings$395.0M$544.0M$449.0M$451.0M$269.0M

Latest News

INVA: What does Argus have to say about INVA? Argus Research · Jul 15, 2026 Is Innoviva (INVA) One of the Best Cheap Small Cap Stocks to Buy Now? Insider Monkey · Jul 1, 2026 Innoviva, Inc. (INVA) Launches Nortiva Bio to Advance Long-Acting Oral Drug Platform Insider Monkey · Jun 25, 2026 Innoviva Specialty Therapeutics (INVA) Partners With Dr. Reddy’s to Expand XACDURO Access Internationally Insider Monkey · Jun 23, 2026 Nortiva Bio Launches to Develop Long-Acting Oral Medicines Business Wire · Jun 18, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$364.0M$202.0M$141.0M$189.0M$197.0M
Investing Cash Flow$42.0M$-57.0M$-67.0M$-64.0M$30.0M
Financing Cash Flow$-454.0M$-122.0M$-76.0M$-15.0M$-5.0M
Net Cash Flow$-45.0M$90.0M$-98.0M$111.0M$246.0M
Free Cash Flow$363.0M$202.0M$141.0M$188.0M$186.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.01
EV / EBITDA1.47
FCF Yield12.45%
Quick Ratio15.18
Interest Coverage8.92
Return 1Y9.96%
Return 3Y60.36%
Return 5Y66.08%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
TBPH $17.03 +0.00% 16.05 $882.64M 0.00%

About Innoviva, Inc.

Innoviva, Inc. is led by CEO Pavel Raifeld, employs 127 people, headquartered in US, publicly traded since 2004.

Innoviva, Inc. (INVA) stock trades at $21.21 with a market capitalization of $1.57B. The stock is valued at a price-to-earnings (P/E) ratio of 4.21, price-to-book of 1.22, price-to-sales of 3.41. Over the past 52 weeks the stock has ranged between $16.52 and $25.15, and currently trades 15.7% below its 52-week high.

On profitability, Innoviva, Inc. generates a return on equity (ROE) of 30.03% — well above the market average, a sign of a high-quality business, return on capital employed of 9.82%, an operating margin of 14.85%, a net profit margin of 80.56%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides